Distribution and predictive performance of the temporal phase of dynamic spot sign appearance in acute intracerebral hemorrhage.


Journal

PloS one
ISSN: 1932-6203
Titre abrégé: PLoS One
Pays: United States
ID NLM: 101285081

Informations de publication

Date de publication:
2020
Historique:
received: 21 04 2020
accepted: 30 06 2020
entrez: 8 8 2020
pubmed: 8 8 2020
medline: 2 10 2020
Statut: epublish

Résumé

Dynamic CT angiography (dCTA) contrast extravasation, known as the "dynamic spot sign", can predict hematoma expansion (HE) in intracerebral hemorrhage (ICH). Recent reports suggest the phase of spot sign appearance is related to the magnitude of HE. We used dCTA to explore the association between the phase of spot sign appearance and HE, clinical outcome, and contrast extravasation rates. We assessed consecutive patients who presented with primary ICH within 4.5 hours from symptom onset who underwent a standardized dCTA protocol and were spot sign positive. The independent variable was the phase of spot sign appearance. The primary outcome was significant HE (either 6 mL or 33% growth). Secondary outcomes included total absolute HE, mortality, and discharge mRS. Mann-Whitney U, Fisher's exact test, and logistic regression were used, as appropriate. Of the 35 patients with spot signs, 27/35 (77%) appeared in the arterial phase and 8/35 (23%) appeared in the venous phase. Thirty patients had follow-up CT scans. Significant HE was seen in 14/23 (60.87%) and 3/7 (42.86%) of arterial and venous cohorts, respectively (p = 0.67). The sensitivity and specificity in predicting significant HE were 82% and 31% for the arterial phase and 18% and 69% for the venous phase, respectively. There was a non-significant trend towards greater total HE, in-hospital mortality, and discharge mRS of 4-6 in the arterial spot sign cohort. Arterial spot signs demonstrated a higher median contrast extravasation rate (0.137 mL/min) compared to venous spot signs (0.109 mL/min). Our exploratory analyses suggest that spot sign appearance in the arterial phase may be more likely associated with HE and poorer prognosis in ICH. This may be related to higher extravasation rates of arterial phase spot signs. However, further studies with larger sample sizes are warranted to confirm the findings.

Sections du résumé

BACKGROUND
Dynamic CT angiography (dCTA) contrast extravasation, known as the "dynamic spot sign", can predict hematoma expansion (HE) in intracerebral hemorrhage (ICH). Recent reports suggest the phase of spot sign appearance is related to the magnitude of HE. We used dCTA to explore the association between the phase of spot sign appearance and HE, clinical outcome, and contrast extravasation rates.
METHODS
We assessed consecutive patients who presented with primary ICH within 4.5 hours from symptom onset who underwent a standardized dCTA protocol and were spot sign positive. The independent variable was the phase of spot sign appearance. The primary outcome was significant HE (either 6 mL or 33% growth). Secondary outcomes included total absolute HE, mortality, and discharge mRS. Mann-Whitney U, Fisher's exact test, and logistic regression were used, as appropriate.
RESULTS
Of the 35 patients with spot signs, 27/35 (77%) appeared in the arterial phase and 8/35 (23%) appeared in the venous phase. Thirty patients had follow-up CT scans. Significant HE was seen in 14/23 (60.87%) and 3/7 (42.86%) of arterial and venous cohorts, respectively (p = 0.67). The sensitivity and specificity in predicting significant HE were 82% and 31% for the arterial phase and 18% and 69% for the venous phase, respectively. There was a non-significant trend towards greater total HE, in-hospital mortality, and discharge mRS of 4-6 in the arterial spot sign cohort. Arterial spot signs demonstrated a higher median contrast extravasation rate (0.137 mL/min) compared to venous spot signs (0.109 mL/min).
CONCLUSION
Our exploratory analyses suggest that spot sign appearance in the arterial phase may be more likely associated with HE and poorer prognosis in ICH. This may be related to higher extravasation rates of arterial phase spot signs. However, further studies with larger sample sizes are warranted to confirm the findings.

Identifiants

pubmed: 32760077
doi: 10.1371/journal.pone.0236196
pii: PONE-D-20-11565
pmc: PMC7410294
doi:

Types de publication

Journal Article Observational Study Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

e0236196

Déclaration de conflit d'intérêts

Co-authors DD and MJH are authors of the Method and System for Identifying Bleeding patent (PAT 80049P-2 US). This does not alter our adherence to PLOS ONE policies on sharing data and materials.

Références

AJNR Am J Neuroradiol. 2011 Nov-Dec;32(10):1879-84
pubmed: 21885714
Stroke. 2016 Mar;47(3):695-700
pubmed: 26846857
Stroke. 2014 Mar;45(3):734-9
pubmed: 24481974
PLoS One. 2014 Mar 03;9(3):e90431
pubmed: 24594897
Stroke. 2009 May;40(5):1672-6
pubmed: 19286577
Can J Neurol Sci. 2009 Jul;36(4):456-61
pubmed: 19650356
Stroke. 2015 Sep;46(9):2498-503
pubmed: 26243220
Neurology. 2011 Apr 5;76(14):1238-44
pubmed: 21346218

Auteurs

Hee Sahng Chung (HS)

Department of Medicine, University of Ottawa, Ottawa, Canada.

Santanu Chakraborty (S)

Department of Medical Imaging, University of Ottawa, Ottawa, Canada.

Michael Reaume (M)

Department of Medicine, University of Ottawa, Ottawa, Canada.

Vignan Yogendrakumar (V)

Department of Medicine, University of Ottawa, Ottawa, Canada.

Matthew J Hogan (MJ)

Department of Medicine, University of Ottawa, Ottawa, Canada.

Dylan Blacquiere (D)

Department of Medicine, University of Ottawa, Ottawa, Canada.

Grant Stotts (G)

Department of Medicine, University of Ottawa, Ottawa, Canada.

Michel Shamy (M)

Department of Medicine, University of Ottawa, Ottawa, Canada.

Richard I Aviv (RI)

Department of Medical Imaging, University of Ottawa, Ottawa, Canada.

Dar Dowlatshahi (D)

Department of Medicine, University of Ottawa, Ottawa, Canada.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH